Iphosphamid

B-ALL

Northern Italy Leukemia GroupPhase 2Dormant

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

6 Active assets in the B-ALL cohort.

Asset / Sponsor	Phase	Rating
VINDESINE Northern Italy Leukemia Group	Phase 2	B
Teniposide Northern Italy Leukemia Group	Phase 2	B
cd22 car-t Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Phase 1/2	CC
cd19/cd22 car-t Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Phase 1/2	CC
Thiscart19A Zhejiang University	Phase 1	CC
CD123-CAR T St. Jude Children's Research Hospital	Phase 1	CC
jy231 Affiliated Hospital of Guangdong Medical University	Early Phase 1	C
MONOCLONAL ANTIBODY BC8 Memorial Sloan Kettering Cancer Center	Early Phase 1	C